Skip to content

Search

Safety evaluation of closed loop system during hypoglyaemic stimuli

The purpose of this study is to evaluate the safety of new system called the Medtronic MinimedTM 670G that has been designed for long term outpatient use.

Feasibility of 24-hour hybrid closed loop insulin delivery in free living conditions

The aim of this study is to see if the Medtronic hybrid closed loop system, a portable artificial pancreas is feasibly to use in the home.

Closed Loop Study - Multicentre

A Closed-Loop System will potentially have a major impact upon acute and chronic complications of diabetes as well as upon their quality of life

Predictive low glucose suspend study – Randomised Controlled trial

Testing a feature of the MiniMed 640G insulin pump, which when used together with a real-time continuous glucose sensor can suspend and resume insulin delivery

How do high protein and/or high fat meals affect postprandial glycaemic control in children using intensive insulin therapy?

Investigating the effect of fat and protein content of a standardised carbohydrate meal on the post-prandial glycaemic response in children with type 1 diabetes

TrialNet: Pathway to Prevention

This study is helping us to learn how type 1 diabetes develop and ways to delay and prevent it.

What life is like living with type 1 diabetes

Every decision a child with type 1 diabetes makes can impact on their blood glucose levels.

A systematic review of the use of artificial intelligence in mental health–based diabetes care: Current applications and future directions

To map and systematise existing research on the use of artificial intelligence (AI) in mental health-based diabetes care contexts, identify trends and potential gaps in the literature, examine methodological limitations and highlight future research directions.

Diabetic Retinopathy Outcomes and Early Worsening of Diabetic Retinopathy in Adolescents and Young Adults With Type 1 Diabetes Following Rapid and Large Glycemic Improvements

Automated insulin delivery (AID) improves glycemia in people with type 1 diabetes (T1D). However, concern remains about early worsening of diabetic retinopathy (EWDR) following rapid and large glycemic improvements. This study evaluated diabetic retinopathy (DR) outcomes in adolescents and young adults with T1D (aged 10-30 years) following AID initiation.